Information Provided By: 
Fly News Breaks for June 26, 2019
DNLI
Jun 26, 2019 | 07:29 EDT
H.C. Wainwright analyst Andrew Fein initiated Denali Therapeutics with a Buy rating and $28 price target, stating that he thinks components of Denali's value pipeline are not fully appreciated by investors. For example, he thinks investors have factored in the utility of Denali's lead candidate, DNL201, in Parkinson's disease patients with LRRK2 mutations, but he believes the upside of the opportunity in the sporadic PD population is not fully accounted for in the stock's valuation.
News For DNLI From the Last 2 Days
There are no results for your query DNLI
